Project description
Innovative oral therapy for Alzheimer’s disease
Alzheimer’s disease (AD) affects millions, and current treatments provide temporary relief. AlzeCure is developing ACD856, a new oral drug designed to boost neurotrophic pathways and improve cognitive function. Additionally, it has a strong safety profile from Phase I trials. The EU-funded NeuroRestore ACD856 project aims to advance ACD856 through a Phase II clinical trial under the EIC Accelerator initiative. This trial seeks to demonstrate the drug’s efficacy. Successful results will lead to an out-licensing agreement with a major pharmaceutical partner, paving the way for a market launch by 2033. AlzeCure’s work supports the European Health Union initiative to reduce the burden of AD.
Objective
Alzheimer’s Disease (AD) is a growing public health crisis, affecting millions of people worldwide with a steady cognitive decline. Current treatments offer only temporary symptomatic relief and fail to address the underlying disease progression. As the population ages, the prevalence of AD is expected to double by 2050, placing an immense burden on caregivers and healthcare systems struggling to provide long-term care.
AlzeCure, a clinical-stage biotech company, has developed ACD856, a first-in-class small molecule designed to treat AD by enhancing neurotrophic pathways such as Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF), which are essential for maintaining neuronal health and cognitive function. ACD856 not only improves cognitive abilities but also has the potential to modify the course of the disease, a breakthrough that sets it apart from existing treatments. Administered orally, it efficiently crosses the blood-brain barrier and has demonstrated a strong safety profile in Phase I trials.
AlzeCure plans to advance ACD856 through a Phase II clinical trial under the EIC Accelerator project, aiming to demonstrate its efficacy and further refine its GMP manufacturing processes. This will trigger an out-licensing agreement with a major pharmaceutical partner, paving the way for a market launch by 2033. The partnership strategy includes milestone payments of up to €250M, positioning ACD856 for blockbuster potential with projected peak annual sales of €7 billion by 2037.
AlzeCure's work aligns with the European Union’s priorities under the European Health Union initiative, aiming to reduce the social and economic burden of AD. ACD856 has the potential to improve patient outcomes, lower healthcare costs by delaying the need for long-term care, and strengthen Europe's leadership in innovative, disease-modifying therapies.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
This project's classification has been human-validated.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
This project's classification has been human-validated.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.1 - The European Innovation Council (EIC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-EIC-ACC - HORIZON EIC Accelerator
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
141 57 Huddinge
Sweden
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.